|
Sep 7
|
Unveiling Novo Nordisk A/S (NVO)'s Value: Is It Really Priced Right? A Comprehensive Guide
|
|
Sep 7
|
Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.
|
|
Sep 7
|
Is Novo Nordisk Stock a Buy Now?
|
|
Sep 6
|
How Novo Nordisk became Europe's most valuable company
|
|
Sep 5
|
Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues
|
|
Sep 5
|
Novo Nordisk Becomes Europe's Most Valuable Company as Wegovy Launches in UK
|
|
Sep 5
|
REFILE-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 5
|
Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus
|
|
Sep 5
|
UPDATE 1-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 5
|
Wegovy maker Novo Nordisk leapfrogs LVMH to become Europe’s most valuable company after it takes its ‘miracle’ weight loss drug to the U.K.
|
|
Sep 5
|
20 Most Addictive Foods According to Science
|
|
Sep 5
|
Trending tickers: Apple l Microsoft l Novo Nordisk l Ashtead
|
|
Sep 5
|
Novo Nordisk Is Now Europe’s Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.
|
|
Sep 5
|
UPDATE 6-Wegovy reaches Britain as NHS, private outlets receive weight loss drug
|
|
Sep 5
|
FTSE and Wall Street lower as pound slides and US factory orders plunge
|
|
Sep 5
|
The ‘miracle’ weight loss drug causing euphoria and fear in Scandinavia
|
|
Sep 5
|
RPT-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 5
|
MORNING BID EUROPE-China optimism dissipates after weak data
|
|
Sep 4
|
CORRECTED (OFFICIAL)-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 4
|
Weight-loss drug maker Novo Nordisk becomes Europe’s most valuable company
|